EQ - NASDAQ
Equillium, Inc.
$3.15
-1.6%Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
At a Glance
Live SnapshotEquillium, Inc. Management Team
Mr. Joel M. Rothman
Chief Development Officer
Mr. Jason A. Keyes
Chief Financial Officer
Dr. Stephen Connelly Ph.D.
Chief Scientific Officer & Director
Compensation
$428,490
Mr. Bruce D. Steel C.F.A.
Co-Founder, President, Chief Executive Officer & Director
Compensation
$471,340
Mr. Daniel Mark Bradbury
Executive Chairman
Compensation
$164,000
Ms. Christine Zedelmayer M.B.A., P.M.P.
Senior Vice President & Chief Operating Officer
Compensation
$415,300
Dr. Matthew Ritter Ph.D.
Senior Vice President of Corporate Development
Penny Tom
Senior Vice President of Finance & Principal Accounting Officer
Dr. Lisette Acevedo
Vice President of Clinical Development
Mr. Michael Moore
Vice President of Investor Relations & Corporate Communications
Equillium, Inc. Insider Positioning
During the last 12 months, insiders have purchased $6.91M and sold $1.26M worth of EQ shares, resulting in $5.64M of net buying activity.
3 Months
0
0.00
250.7K
669.21K
-669K
-$669K
3-6 Months
0
0.00
361.0K
595.59K
-596K
-$596K
6-9 Months
0
0.00
100
98.00
-98
-$98
9-12 Months
4.0M
6.91M
0
0.00
+6.9M
+$6.91M
Top Buyers
Steel Bruce D.
Director, 10 Percent Owner, Officer: President And Ceo
$2.95M
Connelly Stephen
Director, Officer: Chief Scientific Officer
$1.78M
Zedelmayer Christine
Officer: Sr. Vice President And Coo
$1.26M
Tom Penny
Officer: Principal Accounting Officer
$914K
Top Sellers
Zedelmayer Christine
Officer: Sr. Vice President And Coo
$1.06M
Tom Penny
Officer: Principal Accounting Officer
$200K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $5.64M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider buyers vs. 2 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
EQ - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 15, 2026 | May 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 10, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 11, 2024 | May 22, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 11, 2023 | May 22, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 13, 2022 | May 24, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 09, 2021 | May 26, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 03, 2020 | May 19, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 25, 2019 | June 11, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.